Duality Biologics Enhances Collaboration with Adcendo ApS in Oncology
Strengthening the Partnership in Cancer Research
Duality Biologics is excited to announce that Adcendo ApS has decided to exercise its option to utilize our innovative platform. This strategic move further enhances Adcendo's first-in-class antibody-drug conjugate (ADC) pipeline.
Overview of the Collaboration
This collaboration builds upon our existing strategic license agreement, first initiated at the beginning of 2023. Adcendo aims to use Duality's advanced DITAC (Duality Immune Toxin Antibody Conjugates) linker-payload technology for its uPARAP-ADC program, specifically targeting mesenchymal cancers.
Recent Developments in the Partnership
In May 2023, Adcendo made substantial strides by entering into an MTA and Option License Agreement to nominate ADCs against two novel targets. The recent option exercise reflects their commitment to accelerate multiple ADC product candidates into development.
Leadership Insights
Michael Pehl, CEO of Adcendo, expressed enthusiasm about this collaboration, stating, "Our strategic collaboration with Duality enables us to further our mission of developing differentiated ADCs aimed at treating challenging cancers. This partnership not only strengthens our pipeline but also paves the way for becoming leaders in ADC cancer therapy."
Commitment to Innovation
John Zhu, Founder and CEO of Duality Biologics, echoed Pehl's sentiments, emphasizing the shared mission between the two companies. Zhu remarked, "Duality is committed to becoming a frontrunner in the next-generation ADC space. By leveraging our unique strengths together with Adcendo, we can foster innovation in ADC drug development for patients globally."
About Duality Biologics
Duality Biologics is a pioneering clinical-stage biotech firm dedicated to discovering and developing next-generation ADC therapeutics to combat various health challenges, including cancer and autoimmune diseases. Our extensive portfolio includes several state-of-the-art ADC technology platforms protected by global intellectual property rights.
Clinical Trials and Development
We currently have seven clinical-stage ADCs and have conducted numerous global multi-regional clinical trials across multiple countries, enrolling over 1,000 patients. Our research is focused on the development of next-generation “Super ADCs,” including bispecific ADCs, novel mechanisms of action (MOA) ADCs, and therapies aimed at autoimmune conditions.
Contact Information
For further inquiries, reach out to us at IR@dualitybiologics.com.
Frequently Asked Questions
What is the purpose of the collaboration between Duality Biologics and Adcendo ApS?
The collaboration aims to advance antibody-drug conjugate therapies to treat cancers with high unmet medical needs.
What technology platform is Adcendo utilizing from Duality Biologics?
Adcendo is utilizing Duality's proprietary DITAC linker-payload platform for its ADC development programs.
How many clinical-stage ADCs does Duality Biologics have?
Duality Biologics has seven clinical-stage antibody-drug conjugates currently under development.
What types of diseases are targeted by Duality’s ADCs?
Duality’s ADCs focus primarily on cancer but also address autoimmune diseases and other health challenges.
How can I get in touch with Duality Biologics?
You can contact Duality Biologics via email at IR@dualitybiologics.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.